Your browser doesn't support javascript.
loading
Case report: Successful treatment of a rare HER2-positive advanced breast squamous cell carcinoma.
Wang, Gui; Yang, Chenghui; Zeng, Donglin; Wang, Jihao; Mao, Huaxin; Xu, Yu; Jiang, Chao; Wang, Zhen.
Afiliação
  • Wang G; Department of General Surgery, Longquan People's Hospital, Lishui, China.
  • Yang C; Department of Breast Surgery, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Zeng D; Department of Breast Surgery, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Wang J; Department of General Surgery, Longquan People's Hospital, Lishui, China.
  • Mao H; Department of General Surgery, Longquan People's Hospital, Lishui, China.
  • Xu Y; Department of General Surgery, Longquan People's Hospital, Lishui, China.
  • Jiang C; Department of General Surgery, Longquan People's Hospital, Lishui, China.
  • Wang Z; Academy of Chinese Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
Front Pharmacol ; 15: 1332574, 2024.
Article em En | MEDLINE | ID: mdl-38455963
ABSTRACT

Background:

Breast squamous cell carcinoma (SCC) is an uncommon and highly aggressive variant of metaplastic breast cancer. Despite its rarity, there is currently no consensus on treatment guidelines for this specific subtype. Previous studies have demonstrated that chemotherapy alone has limited efficacy in treating breast SCC. However, the potential for targeted therapy in combination with chemotherapy holds promise for future treatment options. Case presentation In this case report, we present a patient with advanced HER2-positive breast SCC, exhibiting a prominent breast mass, localized ulcers, and metastases in the lungs and brain. Our treatment approach involved the administration of HER2-targeted drugs in conjunction with paclitaxel, resulting in a sustained control of tumor growth.

Conclusion:

This case represents a rare occurrence of HER2-positive breast SCC, with limited available data on the efficacy of previous HER2-targeted drugs in treating such patients. Our study presents the first application of HER2-targeted drugs in this particular case, offering novel therapeutic insights for future considerations. Additionally, it is imperative to conduct further investigations to assess the feasibility of treatment options in a larger cohort of patients.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article